Important Note on VCRT: On today's New Profile Vicor Technologies, Inc., something unusually good happened just today. Standard & Poor's initiated "Factual Stock Report Coverage"

Vicor Technologies, Inc. (OTCBB: VCRT)

Dear Members,

On today’s New Profile Vicor Technologies, Inc., something unusually good happened just today. Standard & Poor’s initiated “Factual Stock Report Coverage.”

As you can see from today’s volume, this brought substantial interest to the company.

I encourage you to read today’s release – shown below – or at THIS LINK.

I see exiting things in the weeks ahead. We are left with two market days before Christmas. The great news is that this typically slow time allows you to do incredible due diligence on Vicor.

Our StockGuru Profile is HERE.

Thank you,

John Pentony

Publisher, StockGuru.com

NEW YORK–(BUSINESS WIRE)–Standard & Poor’s announced today that it has commenced Factual Stock Report coverage on Vicor Technologies, Inc.

Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to identify trauma patients in need of a lifesaving intervention, patients at risk of sudden cardiac death, and patients with autonomic dysfunction. Vicor’s diagnostics enable inexpensive, accurate, and early identification of disease states in large at-risk populations (more than a)12 million at-risk cardiac patients, b) 23.7 million diabetics and c) 38 million trauma victims), prior to costly treatments for advanced disease or inaccurate identification. As of November 2009, Vicor was commercializing three proprietary medical diagnostics employing its PD2i® nonlinear algorithm and software: the PD2i Analyzer™, the PD2i VS™ (Vital Sign), and the PD2i CA™ (Cardiac Analyzer).

The PD2i Analyzer™, which is Vicor’s first product, displays and analyzes electrocardiographic (ECG) information to measure heart rate variability (HRV). The PD2i Analyzer™ received 510(k) marketing clearance from the Food and Drug Administration (FDA) in December 2008. Vicor is completing software programming changes for the PD2i Analyzer™ to enable the capture and display of HRV data during paced respiration and controlled exercise. Following completion of these programming changes, the labeling for the original 510(k) will be expanded to include the measurement of HRV during paced respiration and controlled exercise. This expanded labeling will facilitate the use of the PD2i Analyzer™ for screening diabetic and cardiac patients with reimbursement available to the physicians from insurers for these types of tests. Vicor anticipates the PD2i Analyzer™ will be in use in selected physicians practices by the first quarter of 2010, thus permitting initial revenue generation for Vicor.

The PD2i VS™ (Vital Sign), which is in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm and software to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

This report will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts.

About Standard & Poor’s Factual Stock Reports

This Standard & Poor’s service provides factual research coverage enabling information about Vicor Technologies, Inc. and other securities to reach a wide investor audience of Buy and Sell-side investors, helping them understand a company’s fundamentals and business prospects. Currently profiling over 800 issuers, S&P Factual Stock Reports increase market awareness for issuers in the investment community with insightful commentary and key statistics/information. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, Industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is sponsored by the issuer, S&P does not offer investment opinions concerning the advisability of investing in these stocks.

Standard & Poor’s Factual Stock Reports are produced separately from any other analytic activity of Standard & Poor’s. Standard & Poor’s Factual Report research has no access to non-public information received by other units of Standard & Poor’s. Standard & Poor’s does not trade on its own account.

Note: All U.S. and Canadian Companies listed on a National Exchange (not covered by S&P’s STARS research) are eligible to obtain this coverage.

About Standard & Poor’s

Standard & Poor’s, a division of The McGraw-Hill Companies (NYSE: MHP – News), is the world’s foremost provider of financial market intelligence, including independent credit ratings, indices, risk evaluation, investment research and data. With approximately 10,000 employees, including wholly owned affiliates, located in 23 countries, Standard & Poor’s is an essential part of the world’s financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6125340〈=en

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6125340

Vicor Technologies, Inc.
Corporate:
David Fater, 561-995-7313
dfater@vicortech.com
or
Investor:
Cameron Associates
Richard Moyer, 212-554-5466
or
Standard & Poor's
Customer:
Richard Albanese, 212-438-3647
richard_albanese@standardandpoors.com
or
Media Relations:
Michael Privitera, 212-438-6679
michael_privitera@standardandpoors.com

Vicor Technologies, Inc. (OTCBB: VCRT)

Introduction

Vicor Technologies, Inc. (OTCBB: VCRT) is in the crucial transformative stage for a biotechnology company on the verge of becoming a viable commercial enterprise.

This biotechnology company is focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i™ nonlinear algorithm and software which is:

• Highly accurate
• Provides user friendly data acquisition
• Effective for trauma triage easily deployed in a portable monitor
• Provides a simple noninvasive test for identifying patients at risk of sudden cardiac death
• Provides a simple noninvasive test for identifying patients with Diabetic Autonomic Neuropathy

The PD2i Algorithm and software risk stratifies target populations to predict future pathological events. As a predictor of sudden cardiac death it has been shown to be highly accurate, with a sensitivity approaching 100% and a specificity of ~86%.

The advantage of the PD2i™ nonlinear algorithm is that it typically uses recordings made at rest and does not require stress-testing or any active participation from the patient. The test is relatively impervious to data non-stationarities and artifacts, setting it apart from other measures with unparalleled sensitivity.

A large physician shareholder base represents the early adoptees of this Company.

Vicor’s PD2i™ Nonlinear Algorithm is:

• A new vital sign with the ability to actually save lives in both combat and civilian setting
• The PD2i Analyzer™ can capture and display Heart Rate Variability (see defined below) in patients at rest and during paced respiration and controlled exercise.
• Able to identify trauma victims in need of an immediate lifesaving intervention
• Able to be used along with other clinical data to identify patients at risk of sudden cardiac death
• Able to be used along with other clinical data to identify patients who have autonomic dysfunction
• Able to improve trauma triage in real world situations and on the battlefield where time is of the essence and the collection of ‘clean’ data is never guaranteed
• Able to provide consistently accurate results which requires just one to two minutes of EKG data in a trauma setting
• Not derailed in delivering actionable results by noisy raw EKG data
• Functional in trauma environments and battlefield situations

READ THE FULL STOCKGURU PROFILE HERE:

http://www.stockguru.com/about/vicor/

Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.